Actively Recruiting
Evaluation of KSX01-TCRT Injection for Safety and Preliminary Effectiveness in Adults with Refractory or Relapsed Solid Tumors
Led by TCRx Therapeutics Co.Ltd · Updated on 2026-10-26
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and preliminary effectiveness of KSX01-TCRT injection, a personalized TCR-T cell therapy, in adults aged 18 to 70 with refractory or relapsed solid tumors. This early-phase clinical trial focuses on patients whose tumors have not responded to standard treatments or have no standard options available. The study also aims to monitor activation and growth of the TCR-T cells and the participants survival times. Participants receive individualized TCR-T cell injections made from their own immune cells. Eligible patients must have tumors suitable for biopsy to identify acceptable TCR sequences for therapy preparation. The study involves collecting peripheral blood cells to produce autologous TCR-T cells for reinfusion. Women of childbearing age and male participants must use approved contraception during and after treatment as specified. The treatment phase will be monitored closely for safety and tumor response. Throughout the trial, participants undergo regular evaluations including physical fitness scoring, tumor assessments based on RECIST 1.1 criteria, and laboratory tests to confirm adequate organ function. Safety monitoring will continue for about two years to assess adverse events and treatment tolerance. Researchers will also measure tumor response and survival outcomes over this period. Participation requires commitment to all procedures, including blood collections and follow-up visits, to ensure comprehensive evaluation of the investigational therapy.
CONDITIONS
Brief Title
KSX01-TCRT Injection Project in Solid Tumors
Research Team
J
JingChao Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here